| [1] |
Yap JYK, Roberts AJ, Bines JE. Paediatric intestinal failure and transplantation[J]. J Paediatr Child Health, 2020，56(11):1747-1753. DOI: 10.1111/jpc.15052. |
| [2] |
Mutanen A, Lohi J, Merras-Salmio L, et al. Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure[J]. J Hepatol, 2020，28(20):33666-33667. DOI: 10.1016/j.jhep.2020.09.023. |
| [3] |
Gura KM, Mulberg AE, Mitchell PD, et al.Pediatric intestinal failure-associated liver disease: challenges in identifying clinically relevant biomarkers[J]．JPEN J Parenter Enteral Nutr, 2018, 42(2): 455-462. DOI: 10.1177/0148607116671781. |
| [4] |
Courtney CM, Warner BW.Pediatric intestinal failure-associated liver disease[J]. Cur Opin Pediatr, 2017，29(3):363-370. DOI: 10.1097/MOP.0000000000000484. |
| [5] |
Zambrano E, El-Hennawy M, Ehrenkranz RA, et al.Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases[J]. Pediatr Dev Pathol, 2004, 7(5):425-432. DOI: 10.1007/s10024-001-0154-7. |
| [6] |
Fundora J, Aucott S. Intestinal failure-associated liver disease in neonates[J]. Neoreviews, 2020，21(9):e591-e599. DOI: 10.1542/neo.21-9-e591. |
| [7] |
Lavallee CM, MacPherson JAR, Zhou M, et al.Lipid emulsion formulation of parenteral nutrition affects intestinal microbiota and host responses in neonatal piglets[J]. JPEN J Parenter Enteral Nutr, 2017，41(8):1301-1309. DOI： 10.1177/0148607116662972. |
| [8] |
Al-Shahwani NH, Sigalet DL.Pathophysiology, prevention, treatment, and outcomes of intestinal failure-associated liver disease[J]．Pediatr Surg Int, 2017，33(4):405-411. DOI: 10.1007/s00383-016-4042-7. |
| [9] |
Wang P, Wang Y, Lu L, et al.Alterations in intestinal microbiota relate to intestinal failure-associated liver disease and central line infections[J]．J Pediatr Surg, 2017，52(8):1318-1326. DOI： 10.1016/j.jpedsurg.2017.04.020. |
| [10] |
Vanek VW, Seidner DL, Allen P, et al.A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions[J]．Nutr Clin Pract，2012，27(2):150-192. DOI: 10.1177/0884533612439896. |
| [11] |
Raman M, Almutairdi A, Mulesa L, et al.Parenteral nutrition and lipids[J]. Nutrients, 2017，9(4):388. DOI： 10.3390/nu9040388. |
| [12] |
Turner JM, Josephson J, Field CJ, et al.Liver Disease, systemic inflammation, and growth using a mixed parenteral lipid emulsion, containing soybean oil, fish oil, and medium chain triglycerides, compared with soybean oil in parenteral nutrition-fed neonatal piglets[J]. JPEN J Parenter Enteral Nutr, 2016，40(7):973-981. DOI： 10.1177/0148607115579711. |
| [13] |
Lee WS, Chew KS, Ng RT, et al.Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management[J]．Hepatol Int，2020，14(3):305-316. DOI: 10.1007/s12072-020-10048-8. |
| [14] |
Goulet OJ, Cai W, Seo JM. Lipid emulsion use in pediatric patients requiring long-term parenteral nutrition[J]．JPEN J Parenter Enteral Nutr, 2020，44(Suppl 1):S55-S67. DOI: 10.1002/jpen.1762. |
| [15] |
Lavallee CM, Lim DW, Wizzard PR, et al.Impact of clinical use of parenteral lipid emulsions on bile acid metabolism and composition in neonatal piglets[J]. JPEN J Parenter Enteral Nutr, 2019, 43(5): 668-676. DOI： 10.1002/jpen.1437. |
| [16] |
Ishihara T, Yoshida M, Arita M．Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis[J]．Int Immunol, 2019，31(9): 559-567. DOI: 10.1093/intimm/dxz001. |
| [17] |
Costa S, Iannotta R, Maggio L, et al.Fish oil-based lipid emulsion in the treatment of parenteral nutrition-associated cholestasis[J]. Italian J Pediatr，2018，44(1):101. DOI: 10.1186/s13052-018-0539-0. |
| [18] |
Zhang T, Wang N, Yan W, et al.Effect of a fish oil-based lipid emulsion on intestinal failure-associated liver disease in children[J]．Eur J Clin Nutrit，2018，72(10):1364-1372. DOI： 10.1038/s41430-018-0096-z. |
| [19] |
Honeywell S, Zelig R, Rigassio Radler D. Impact of intravenous lipid emulsions containing fish oil on clinical outcomes in critically Ⅲ surgical patients: a literature review[J]. Nutr Clin Pract, 2019, 34(1): 112-122. DOI: 10.1002/ncp.10224. |
| [20] |
Lam HS, Tam YH, Poon TCW, et al.A double-blind randomised controlled trial of fish oil-based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis[J]．Neonatology, 2014，105(4):290-296. DOI： 10.1159/000358267. |
| [21] |
Nandivada P, Fell GL, Mitchell PD, et al.Long-term fish oil lipid emulsion use in children with intestinal failure-associated liver disease[J]．JPEN J Parenter Enteral Nutr，2017，41(6):930-937.DOI： 10.1177/0148607116633796. |
| [22] |
Soden JS, Lovell MA, Brown K, et al.Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure[J]．J Pediatr，2010, 156(2): 327-331. DOI： 10.1016/j.jpeds.2009.08.033. |
| [23] |
Belza C, Thompson R, Somers GR, et al.Persistence of hepatic fibrosis in pediatric intestinal failure patients treated with intravenous fish oil lipid emulsion[J]. J Pediatr Surg, 2017，52(5): 795-801.DOI: 10.1016/j.jpedsurg.2017.01.048. |
| [24] |
Wang C, Venick RS, Shew SB, et al. Long-term outcomes in children with intestinal failure-associated liver disease treated with 6 months of intravenous fish oil followed by resumption of intravenous soybean oil[J]. JPEN J Parenter Enteral Nutr, 2019，43(6):708-716. DOI: 10.1002/jpen.1463. |
| [25] |
Khalaf RT, Sokol RJ.New insights into intestinal failure-associated liver disease in children[J]. Hepatology, 2020，71(4):1486-1498. DOI: 10.1002/hep.31152. |
| [26] |
Riedy M, DePaula B, Puder M, et al.Higher doses of fish oil-based lipid emulsions used to treat inadequate weight gain and rising triene：tetraene ratio in a severely malnourished infant with intestinal failure-associated liver disease[J]．JPEN J Parenter Enteral Nutr，2017，41(4):667-671. DOI: 10.1177/0148607116661031. |
| [27] |
Gura KM, Calkins KL, Puder M．Use of fish oil intravenous lipid emulsions as monotherapy in the pediatric intestinal failure patient: beyond the package insert[J]．Nutr Clin Pract，2020，35(1): 108-118. DOI: 10.1002/ncp.10413. |
| [28] |
Le HD, de Meijer VE, Zurakowski D, et al.Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition-associated liver disease[J]. JPEN J Parenter Enteral Nutr，2010，34(5):477-484. DOI: 10.1177/0148607110371806. |
| [29] |
Nandivada P, Baker MA, Mitchell PD, et al.Predictors of failure of fish-oil therapy for intestinal failure-associated liver disease in children[J]．Am J Clin Nutr，2016，104(3): 663-670. DOI: 10.3945/ajcn.116.137083. |
| [30] |
Calkins KL, Dunn JC, Shew SB, et al. Pediatric intestinal failure-associated liver disease is reversed with 6 months of intravenous fish oil[J]. JPEN J Parenter Enteral Nutr, 2014，38(6):682-692. DOI: 10.1177/0148607113495416. |
| [31] |
Lapillonne A, Fidler Mis N, Goulet O, et al.ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: lipids[J]．Clin Nutr，2018，37(6 Pt B): 2324-2336. DOI: 10.1016/j.clnu.2018.06.946. |
| [32] |
Raphael BP, Mitchell PD, Gura KM, et al.Growth in infants and children with intestinal failure-associated liver disease treated with intravenous fish oil[J]．J Pediatr Gastroenterol Nutr, 2020，70(2):261-268. DOI: 10.1097/MPG.0000000000002551. |
| [33] |
Biagetti C, Correani A, D′Ascenzo R, et al.Does intravenous fish oil affect the growth of extremely low birth weight preterm infants on parenteral nutrition？[J]. Clin Nutr, 2019, 38(5):2319-2324. DOI： 10.1016/j.clnu.2018.10.009. |
| [34] |
Gura K, Premkumar MH, Calkins KL, et al.Intravenous fish oil monotherapy as a source of calories and fatty acids promotes age-appropriate growth in pediatric patients with intestinal failure-associated liver disease[J]. J Pediatr, 2020，219:98.e4-105.e4. DOI: 10.1016/j.jpeds.2019.12.065. |
| [35] |
Carta G, Murru E, Vargiu R, et al.Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat′s tissues[J]．Prostaglandins Leukot Essent Fatty Acids，2020，153: 102053. DOI： 10.1016/j.plefa.2020.102053. |
| [36] |
Olthof ED, Roelofs HM, Fisk HL, et al.No clinical or biochemical evidence for essential fatty acid deficiency in home patients who depend on long-term mixed olive oil- and soybean oil-based parenteral nutrition[J]. JPEN J Parenter Enteral Nutr, 2016，40(7):982-988.DOI： 10.1177/0148607115581375. |
| [37] |
Gramlich L, Ireton-Jones C, Miles JM, et al.Essential fatty acid requirements and intravenous lipid emulsions[J]. JPEN J Parenter Enteral Nutr, 2019，43(6):697-707. DOI： 10.1002/jpen.1537. |
| [38] |
Lezo A, D′Onofrio V, Puccinelli MP, et al. Plasma and red blood cell PUFAs in home parenteral nutrition paediatric patients-effects of lipid emulsions[J]. Nutrients, 2020，12(12):E3748. DOI: 10.3390/nu12123748. |
| [39] |
Ong ML, Venick RS, Shew SB, et al.Intravenous fish oil and serum fatty acid profiles in pediatric patients with intestinal failure-associated liver disease[J]. JPEN J Parenter Enteral Nutr，2019, 43(6):717-725. DOI: 10.1002/jpen.1532. |
| [40] |
Dicken BJ, Bruce A, Samuel TM, et al.Bedside to bench: The risk of bleeding with parenteral omega-3 lipid emulsion therapy[J]．J Pediatr，2014，164(3):652-654. DOI： 10.1016/j.jpeds.2013.10.066. |
| [41] |
Turner JM, Field CJ, Goruk S, et al.Platelet arachidonic acid deficiency may contribute to abnormal platelet function during parenteral fish oil monotherapy in a piglet model[J]．JPEN J Parenter Enteral Nutr，2016，40(4): 587-591. DOI: 10.1177/0148607114568670. |
| [42] |
Dao DT, Anez-Bustillos L, Finkelstein AM, et al.Trends of INR and fecal excretion of vitamin K during cholestasis reversal: implications in the treatment of neonates with intestinal failure-associated liver disease[J]. JPEN J Parenter Enteral Nutr，2020，44(5):951-958. DOI： 10.1002/jpen.1677. |
| [43] |
Nandivada P, Anez-Bustillos L, O′Loughlin AA, et al.Risk of post-procedural bleeding in children on intravenous fish oil[J]．Am J Surg，2017，214(4):733-737. DOI: 10.1016/j.amjsurg.2016.10.026. |
| [44] |
Akintoye E, Sethi P, Harris WS, et al.Fish oil and perioperative bleeding[J]．Circ Cardiovasc Qual Outcomes，2018, 11(11):e004584. DOI: 10.1161/CIRCOUTCOMES.118.004584. |
| [45] |
Gura KM. The power of networking and lessons learned from omegaven[J]. J Pediatr Pharmacol Ther, 2020，25(8):663-674. DOI: 10.5863/1551-6776-25.8.663. |